Actavis sells off Chinese subsidiary


Generic drugs heavyweight Actavis is selling off a subsidiary based in Foshan, China. The business is being bought by Zhejiang Chiral Medicine Chemicals for an undisclosed sum.

In a company statement, Actavis stressed that the company ‘intends to continue further commercial operations in China in collaboration with its preferred business partners’. But in an interview with Bloomberg, chief executive Paul Bisaro claimed that doing business in China is ‘too risky’, and the returns were not worth the effort compared to other markets.


Related Content

Allergan steps away from generics with sale to Teva

29 July 2015 Business

news image

$40.5 billion deal gives Allergan cash to clear debt and fund further acquisitions, and catapults Teva into global pharma top...

UCB sells speciality generics subsidiary

26 November 2014 Business

news image

Firm will use $1.5bn proceeds to reduce debt and concentrate on developing new drugs in neurology and immunology

Most Commented

WHO clarifies glyphosate risks

23 May 2016 Business

news image

UN and WHO panel conclude the herbicide glyphosate is ‘unlikely’ to cause cancer at realistic exposure levels

Large HIV vaccine trial to launch in South Africa

24 May 2016 News and Analysis

news image

US funding agency will enlist 5400 people for HIV vaccine study in South Africa in November